Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytori Therapeutics, a developer and marketer of medical technologies, has announced that a US patent has been issued to the University of California, that covers a population of stem cells, progenitor cells and other replicating cells, which can be obtained from human adipose tissue.
Subscribe to our email newsletter
The composition of matter patent is licensed to Cytori through its agreement with the University of California.
The patent broadens Cytori’s current patent portfolio for adipose-derived cell therapies and strengthens the company’s ability to freely develop future generation therapeutics, said Cytori.
The cells covered by the issued claims are believed to encompass a clinically important subpopulation of cells within the adipose tissue. The subpopulation of human cells described in the patent was defined by characterizing specific cell surface markers for cells, which posses the ability to self replicate and differentiate toward one or more lineages.
Specifically, the newly issued claims are directed to cells expressing certain combinations of STRO-1+, CD29+, CD44+, CD71+, CD49D+, CD90+, CD105+, SH3, CD45-, CD31- and low or undetectable levels of CD106. Such cell surface marker studies are a robust method of describing stem and other cells and were performed at the University of California, the company said.
The patent application containing these claims is jointly owned by the University of California and the University of Pittsburgh.